The role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarction

Postepy w Kardiologii Interwencyjnej

Volumn 10, Issue 1, 2014, Pages 12-17

  Akturk, Ibrahim Faruk ^a   Yalcin, Ahmet Arif ^a   Biyik, Ismail ^b   Caglar, Nihan Turhan ^c   Isiksacan, Nilgun ^a   Sarikamis, Cetin ^a   Uzun, Fatih ^a   Celik, Omer ^a   Caglar, Ilker Murat ^d  

^a MEHMET AKIF ERSOY THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Usak State Hospital   (Turkey)

^c Department of Cardiology Istanbul Education and Research Hospital ^*  (Turkey)

^d BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Coronary artery disease; Insulin like growth factor 1; No reflow; ST elevation myocardial infarction

Indexed keywords

CREATININE; GLUCOSE; LOW DENSITY LIPOPROTEIN; SOMATOMEDIN C; TRIACYLGLYCEROL; TROPONIN;

ADULT; ANGIOGRAPHY DEVICE; ARTICLE; CARDIAC PATIENT; CASE CONTROL STUDY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENSINI SCORE; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; NO REFLOW PHENOMENON; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYNTAX SCORE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84898471815     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2014.41460     Document Type: Article

References (30)

1. Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2684-2690.
2. Higashi Y, Sukhanov S, Anwar A, et al. Aging, atherosclerosis, and IGF-1. J Gerontol A Biol Sci Med Sci 2012; 67: 626-639.
3. Burchardt P, Gozdzicka-Jozefiak A, Zurawski J, et al. Are elevated levels of IGF-1 caused by coronary arteriesoclerosis? Molecular and clinical analysis. Protein J 2010; 29: 538-544.
4. Rezkella SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome and effect of pharmacologic therapy. J Interv Cardiol 2010; 23: 429-436.
5. Tanzilli G, Greco C, Pasceri V, et al. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty. Catheter Cardiovasc Interv 2010; 76: 787-793.
6. Niccoli G, Marino M, Spaziani C, Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010; 12: 81-91.
7. Werner GS, Lang K, Kuehnert H, Figulla HR. Intrcoronary verapamil for reversal of no reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002; 57: 444-451.
8. Gibson MC, Schoming A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096-3105.
9. Petronio AS, De Carlo M, Cibatti N, et al. Left ventricular remedoling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005; 150: 1015.
10. Bhavsar J, Rosenson R. Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. Clin Hemorheol Microcirc 2010; 44: 193-205.
11. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no reflow after percutaneous coronary intervention. Circulation 1994; 89: 2514-2518.
12. Krebs A, Wallaschofski H, Spilcke-Liss E, et al. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med 2008; 46: 1776-1783.
13. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase 1 findings. N Engl J Med 1985; 312: 932-936.
14. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
15. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219-227.
16. Burchardt P, Tabaczewski P, Gozìdzicka-Józefiak A, et al. Association between insulin like growth factor-1 and lipoprotein metabolism in stable angina patients on statin therapy: a pilot study. Kardiol Pol 2012; 70: 1017-1102.
17. Eekuri C, Arslan Ö, Ütük O, et al. Serum level of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis. Anadolu Kardiyol Derg 2004; 4: 209-212.
18. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28: 440-448.
19. Prêle CM, Reichelt ME, Mutsaers SE, et al. Insulin-like growth factor-1 overexpression in cardiomyocytes diminishes ex vivo heart functional recovery after acute ischemia. Cardiovasc Pathol 2012; 21: 17-27.
20. Li J, Stenbøg E, Bush A, et al. Insulin-like growth factor 1 improves the relationship between systemic oxygen consumption and delivery in piglets after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2004; 127: 1436-1441.
21. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor- I and angiographically documented coronary artery disease. Am J Cardiol 1996; 77: 200-202.
22. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin- like growth factor-I in the acute phase of myocardial infarction. J Am Coll Cardiol 2001; 38: 26-32.
23. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000; 35: 647-654.
24. Botker HE, Skjaerbaek C, Eriksen UH, et al. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol 1997; 79: 961-963.
25. Lawlor AD, Ebrahim S, Smith GD, et al. The association of insulin- like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis 2008; 201: 198-204.
26. Miller M. Lipid levels in the post-acute coronary syndrome setting. J Am Coll Cardiol 2008; 51: 1446-1447.
27. Pitt B, Loscalzo J, Ycüas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51: 1440-1445.
28. Sönmez O, Erta G, Bacaksz A, et al. Relation of neutrophil- to-lymphocyte ratio with the presence and complexity of coronary artery disease: an observational study. Anadolu Kardiyol Derg 2013; 13: 662-7.
29. Balta S, Demirkol S, Unlu M, et al. Neutrophil to lymphocyte ratio may be predictor of mortality in all conditions. Br J Cancer 2013; 109: 3125-6.
30. Harrison RW, Aggarwal A, Ou FS, et al.; American College of Cardiology National Cardiovascular Data Registry. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111: 178-184.